Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial …
H Minatogawa, N Izawa, K Shimomura… - British Journal of …, 2024 - nature.com
Background This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with
sparing on days 2–4 in cisplatin-based chemotherapy. Methods Patients with malignant …
sparing on days 2–4 in cisplatin-based chemotherapy. Methods Patients with malignant …
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial …
H Minatogawa, N Izawa, K Shimomura… - British Journal of …, 2024 - tohoku.elsevierpure.com
Background: This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with
sparing on days 2–4 in cisplatin-based chemotherapy. Methods: Patients with malignant …
sparing on days 2–4 in cisplatin-based chemotherapy. Methods: Patients with malignant …
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial …
H Minatogawa, N Izawa, K Shimomura… - British Journal of …, 2023 - europepmc.org
This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on
days 2-4 in cisplatin-based chemotherapy. Patients with malignant solid tumors who were …
days 2-4 in cisplatin-based chemotherapy. Patients with malignant solid tumors who were …
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial …
H Minatogawa, N Izawa, K Shimomura… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Background This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with
sparing on days 2-4 in cisplatin-based chemotherapy. Methods Patients with malignant solid …
sparing on days 2-4 in cisplatin-based chemotherapy. Methods Patients with malignant solid …